LONDON (Alliance News) - Sareum Holdings PLC said Monday it has been granted a patent for an invention associated to its CHK1 cancer programme with the Cancer Research Technology Pioneer Fund and BACIT Ltd by the European Office.
The patent covers compounds that inhibit CHK1 kinase enzyme function and their potential to treat cancer, either in combination with chemotherapy or radiotherapy.
Sareum has also been granted this patent in the US.
"The intellectual property that underpins the CHK1 cancer programme continues to develop, protecting the asset and enhancing its commercial value," said Chief Executive Tim Mitchell in a statement.
Shares in Sareum were trading up 2.2% at 0.460 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Sareum (SAR)